Vertex announces broad reimbursement agreement with nhs england for alyftrek® (deutivacaftor/tezacaftor/vanzacaftor) an innovative once-daily cftr modulator for the treatment of cystic fibrosis

London--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) announced today that it has reached a broad reimbursement agreement with nhs england for vertex's cystic fibrosis (cf) medicine alyftrek® (deutivacaftor/tezacaftor/vanzacaftor). this agreement comes as the national institute for health and care excellence (nice) has issued a positive final draft recommendation for this medicine. this next-in-class triple combination treatment is licensed for people living with cf aged 6.
VRTX Ratings Summary
VRTX Quant Ranking